Martín Cullell-Young

993 total citations
32 papers, 681 citations indexed

About

Martín Cullell-Young is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Martín Cullell-Young has authored 32 papers receiving a total of 681 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 14 papers in Molecular Biology and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Martín Cullell-Young's work include Lung Cancer Research Studies (9 papers), Cancer therapeutics and mechanisms (7 papers) and Lung Cancer Treatments and Mutations (7 papers). Martín Cullell-Young is often cited by papers focused on Lung Cancer Research Studies (9 papers), Cancer therapeutics and mechanisms (7 papers) and Lung Cancer Treatments and Mutations (7 papers). Martín Cullell-Young collaborates with scholars based in Spain, United States and France. Martín Cullell-Young's co-authors include Antonio Celada, Annabel F. Valledor, Francesc E. Borràs, Carmen Kahatt, Mariano Siguero, Sergio Szyldergemajn, Josep Tabernero, Pilar Lardelli, Luis Paz‐Ares and Víctor Moreno and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and British Journal of Cancer.

In The Last Decade

Martín Cullell-Young

31 papers receiving 673 citations

Peers

Countries citing papers authored by Martín Cullell-Young

Since Specialization

Citations

This map shows the geographic impact of Martín Cullell-Young's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martín Cullell-Young with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martín Cullell-Young more than expected).

Fields of papers citing papers by Martín Cullell-Young

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martín Cullell-Young. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martín Cullell-Young. The network helps show where Martín Cullell-Young may publish in the future.

Co-authorship network of co-authors of Martín Cullell-Young

This figure shows the co-authorship network connecting the top 25 collaborators of Martín Cullell-Young. A scholar is included among the top collaborators of Martín Cullell-Young based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martín Cullell-Young. Martín Cullell-Young is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase I results on the efficacy, safety and pharmacokinetics of lurbinectedin and irinotecan in advanced solid tumors 2025 ·Investigational New Drugs ·Alejandro Falcón, Santiago Ponce, Gregory M. Coté, (unknown), W. Marston Linehan, Bruno Bockorny, (unknown), Carmen Kahatt, Sara Martínez, Pablo Zubiaur, Mariano Siguero, Martín Cullell-Young, (unknown), Jon Zugazagoitia, Luis Paz‐Ares	0
2	Pooled Safety Analysis of Single-Agent Lurbinectedin in Patients With Advanced Solid Tumours 2023 ·European Journal of Cancer ·Alexandra Léary, Ana Oaknin, José Trigo, Víctor Moreno, Jean‐Pierre Delord, Valentina Boni, Irene Braña, Cristian Fernández, Carmen Kahatt, Antonio Nieto, Martín Cullell-Young, Ali Zeaiter, Vivek Subbiah	10
3	Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study 2022 ·Clinical Cancer Research ·Vivek Subbiah, Irene Braña, Alessandra Longhi, Valentina Boni, Jean‐Pierre Delord, Ahmad Awada, Pascaline Boudou‐Rouquette, John Sarantopoulos, Geoffrey I. Shapiro, Anthony Elias, Ravin Ratan, Cristian Fernández, Carmen Kahatt, Martín Cullell-Young, Mariano Siguero, Ali Zeaiter, Sant P. Chawla	18
4	Antitumor activity of lurbinectedin in combination with oral capecitabine in patients with metastatic breast cancer 2022 ·ESMO Open ·Ahmad Awada, Valentina Boni, Víctor Moreno, (unknown), Carmen Kahatt, (unknown), Mariano Siguero, Carlos Fernández‐Teruel, Martín Cullell-Young, Josep Tabernero	2
5	Phase I study of lurbinectedin in combination with weekly paclitaxel with or without bevacizumab in patients with advanced solid tumors 2022 ·Investigational New Drugs ·Emiliano Calvo, Cristiana Sessa, Guilherme Harada, Maria J. de Miguel, Carmen Kahatt, (unknown), Mariano Siguero, Carlos Fernández‐Teruel, Martín Cullell-Young, Anastasios Stathis, Alexander Drilon	6
6	Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I study 2021 ·Investigational New Drugs ·M.E. Olmedo, Martin Förster, Víctor Moreno, (unknown), Irene Braña, Michael Flynn, Bernard Doger, Maria J. de Miguel, José Antonio López-Vilariño, Rafael N. Nuñez, Carmen Kahatt, Martín Cullell-Young, Ali Zeaiter, Emiliano Calvo	14
7	P2.12-13 Lurbinectedin (L) Combined with Paclitaxel (P) or Irinotecan (I) in Relapsed SCLC. Results from Two Phase Lb Trials 2019 ·Journal of Thoracic Oncology ·Santiago Ponce, Emiliano Calvo, Maria J. de Miguel, C. Sessa, M.J. Flor, A. Drilon, Alejandro Falcón, Ioan Şimon, Ramiro Manzano-Núñez, (unknown), (unknown), José Antonio López-Vilariño, Salvador Fudio, Mariano Siguero, Martín Cullell-Young, Carmen Kahatt, Ali Zeaiter, Luis Paz‐Ares	3
8	Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study 2017 ·Annals of Oncology ·Emiliano Calvo, Víctor Moreno, Michael Flynn, Esther Holgado, M.E. Olmedo, (unknown), Carmen Kahatt, José Antonio López-Vilariño, Mariano Siguero, Carlos Fernández‐Teruel, Martín Cullell-Young, (unknown), Martin Förster	65
9	Higher antitumor activity of trabectedin in germline BRCA2 carriers with advanced breast cancer as compared to BRCA1 carriers: A subset analysis of a dedicated phase II trial 2017 ·The Breast ·(unknown), Suzette Delaloge, Pilar Lardelli, Carmen Kahatt, Tomasz Byrski, Joanne L. Blum, Anthony Gonçalvès, Mario Campone, Antonio Nieto, Vicente Alfaro, Martín Cullell-Young, Jan Lubiński	18
10	A phase II trial of trabectedin in triple-negative and HER2-overexpressing metastatic breast cancer 2016 ·Breast Cancer Research and Treatment ·Joanne L. Blum, Anthony Gonçalvès, Noa Efrat, Marc Debled, Pierfranco Conté, Paul Richards, Donald Richards, Pilar Lardelli, Antonio Nieto, Martín Cullell-Young, Suzette Delaloge	15
11	Activity of trabectedin in germline BRCA1/2-mutated metastatic breast cancer: results of an international first-in-class phase II study 2014 ·Annals of Oncology ·Suzette Delaloge, (unknown), Tomasz Byrski, Joanne L. Blum, Anthony Gonçalvès, Mario Campone, Pilar Lardelli, Carmen Kahatt, Antonio Nieto, Martín Cullell-Young, Jan Lubiński	31
12	A phase I pharmacokinetic study of PM00104 (Zalypsis®) administered as a 24-h intravenous infusion every 3 weeks in patients with advanced solid tumors 2013 ·Cancer Chemotherapy and Pharmacology ·Jaume Capdevila, Sally Clive, E. Casado, Caroline O. Michie, Adelaida Piera, Elisabet Sicart, (unknown), (unknown), Carmen Kahatt, (unknown), (unknown), Mariano Siguero, Martín Cullell-Young, Josep Tabernero	7
13	Phase I–II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma 2013 ·British Journal of Cancer ·Ruth Plummer, Paul Lorigan, Ewan Brown, Renata Zaucha, Vladimir Moiseyenko, Lev Demidov, Vincent Soriano, Ewa Chmielowska, Raquel Andrés, (unknown), Carmen Kahatt, Sergio Szyldergemajn, (unknown), (unknown), Martín Cullell-Young, Hilary Calvert	23
14	Phase I study of weekly kahalalide F as prolonged infusion in patients with advanced solid tumors 2013 ·Cancer Chemotherapy and Pharmacology ·Ramón Salazar, H. Cortés-Funes, E. Casado, Beatriz Pardo, Ana López, (unknown), Josep Tabernero, (unknown), Margarita García, (unknown), (unknown), Martín Cullell-Young, (unknown), Luis Paz‐Ares	25
15	A phase I and pharmacokinetic study of elisidepsin (PM02734) in patients with advanced solid tumors 2012 ·Cancer Chemotherapy and Pharmacology ·Ramón Salazar, Robert J. Jones, Ana Oaknin, D. Crawford, (unknown), C. A. Hopkins, Marta Gil, (unknown), Arturo Soto-Matos, Martín Cullell-Young, (unknown), T.R. Jeffry Evans	17
16	Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin's lymphoma 2012 ·Haematologica ·(unknown), Dolores Caballero, Christophe Fermé, Emanuele Zucca, R. Arranz, Javier Briones, Christian Gisselbrecht, Gilles Salles, Alessandro M. Gianni, Henry Gómez, Carmen Kahatt, Chiara Corrado, Sergio Szyldergemajn, (unknown), (unknown), Martín Cullell-Young, Franco Cavalli	52
17	Phase II Study of Plitidepsin 3-Hour Infusion Every 2 Weeks in Patients With Unresectable Advanced Medullary Thyroid Carcinoma 2010 ·American Journal of Clinical Oncology ·Éric Baudin, (unknown), Luis Paz‐Ares, Allan T. van Oosterom, Martín Cullell-Young, Martin Schlumberger	23
18	A phase I dose-escalating study of ES-285, a marine sphingolipid-derived compound, with repeat dose administration in patients with advanced solid tumors 2010 ·Investigational New Drugs ·Eduardo Vilar, Viktor Grünwald, Patrick Schöffski, (unknown), Ramón Salazar, J. L. Mesías Iglesias, (unknown), Martín Cullell-Young, José Baselga, Josep Tabernero	17
19	Abbreviated Clinical Study Reports with Investigational Medicinal Products for Human Use: Current Guidelines and Recommendations 2007 ·Croatian Medical Journal ·Vicente Alfaro, Martín Cullell-Young, Adnan Tanovı́c	7
20	From transcription to cell surface expression, the induction of MHC class II I-Aα by interferon-γ in macrophages is regulated at different levels 2001 ·Immunogenetics ·Martín Cullell-Young, Marta Barrachina, Carlos López, E. Goñalons, Jorge Lloberas, Concepció Soler, Antonio Celada	28

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact